Acumen Pharmaceuticals, Inc. (ABOS) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Acumen Pharmaceuticals Reports Financial Results for Second Quarter 2022 and Business Highlights
August 15, 2022 4:05 PM EDTTopline results expected in the first half of 2023 from INTERCEPT-AD, a multi-center, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose Phase 1 clinical trial of ACU193 in patients with early Alzheimers disease (AD)
Key methods and assay model developed to potentially standardize the study of soluble amyloid-beta oligomers (AOs) presented in a poster at the recent Alzheimers Association International Conference (AAIC)$209.9 million in cash, cash equivalents and marketable securities as of June 30, 2022, which is expected to provide cash... More
